Skip to content
TrialScanner

NCT03058289

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Registry record

Lead sponsor
Intensity Therapeutics, Inc.
Conditions
Breast Cancer; Head and Neck Cancer; Squamous Cell Carcinoma; Lymphoma; Pancreatic Cancer
Primary completion
Feb 22, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03058289 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03058289: A Phase 1/2 Safety Study of... | TrialScanner